AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

AgomAb Therapeutics NV Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-56.88	-46.27	-11.39
Depreciation & Amortization	-	0.31	0.1
Share-Based Compensation	-	1.07	2.16
Other Operating Activities	5.87	-1.94	-15.46
Operating Cash Flow	-51.01	-46.83	-24.59
Change in Investments	-	-	40
Other Investing Activities	-0.52	-0.68	-
Investing Cash Flow	-0.88	-0.68	40
Dividends Paid	-	-0.68	-
Share Issuance / Repurchase	-	97.06	79.87
Debt Issued / Paid	-	-0.16	-0.1
Other Financing Activities	81.56	0.55	-0.45
Financing Cash Flow	81.56	96.76	79.32
Net Cash Flow	27.19	49.26	94.73
Free Cash Flow	-51.37	-47.5	-24.59

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).